Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via Spray-Drying Enhances Their Uptake in the Olfactory Mucosa.

Frontiers in pharmacology

Spindler LM, Feuerhake A, Ladel S, Günday C, Flamm J, Günday-Türeli N, Türeli E, Tovar GEM, Schindowski K, Gruber-Traub C.
PMID: 34539414
Front Pharmacol. 2021 Sep 01;12:732954. doi: 10.3389/fphar.2021.732954. eCollection 2021.

Intranasal delivery has gained prominence since 1990, when the olfactory mucosa was recognized as the window to the brain and the central nervous system (CNS); this has enabled the direct site specific targeting of neurological diseases for the first...

Screening of Surfactants for Improved Delivery of Antimicrobials and Poly-Lactic-.

Pharmaceutics

Rancan F, Jurisch J, Günday C, Türeli E, Blume-Peytavi U, Vogt A, Schaudinn C, Günday-Türeli N.
PMID: 34371785
Pharmaceutics. 2021 Jul 17;13(7). doi: 10.3390/pharmaceutics13071093.

Topical wound management is often a challenge due to the poor penetration of antimicrobials in wound tissue and across the biofilm matrix where bacteria are embedded. Surfactants have been used for decades to improve the stability of formulations, increase...

Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms.

Drug delivery and translational research

Juntke J, Murgia X, Günday Türeli N, Türeli AE, Thorn CR, Schneider M, Schneider-Daum N, de Souza Carvalho-Wodarz C, Lehr CM.
PMID: 34047967
Drug Deliv Transl Res. 2021 Aug;11(4):1752-1765. doi: 10.1007/s13346-021-01002-8. Epub 2021 May 28.

The major pathogen found in the lungs of adult cystic fibrosis (CF) patients is Pseudomonas aeruginosa, which builds antibiotic-resistant biofilms. Pulmonary delivery of antibiotics by inhalation has already been proved advantageous in the clinic, but the development of novel...

The solid progress of nanomedicine.

Drug delivery and translational research

Martins JP, das Neves J, de la Fuente M, Celia C, Florindo H, Günday-Türeli N, Popat A, Santos JL, Sousa F, Schmid R, Wolfram J, Sarmento B, Santos HA.
PMID: 32141035
Drug Deliv Transl Res. 2020 Jun;10(3):726-729. doi: 10.1007/s13346-020-00743-2.

This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers...

Key for crossing the BBB with nanoparticles: the rational design.

Beilstein journal of nanotechnology

Lombardo SM, Schneider M, Türeli AE, Günday Türeli N.
PMID: 32551212
Beilstein J Nanotechnol. 2020 Jun 04;11:866-883. doi: 10.3762/bjnano.11.72. eCollection 2020.

Central nervous system diseases are a heavy burden on society and health care systems. Hence, the delivery of drugs to the brain has gained more and more interest. The brain is protected by the blood-brain barrier (BBB), a selective...

Showing 1 to 5 of 5 entries